Kristina Hasselgren1, Bengt Isaksson2, Bjarne Ardnor3, Gert Lindell4, Magnus Rizell5, Cecilia Strömberg6, Per Loftås1, Bergthor Björnsson1, Per Sandström1. 1. Department of Surgery and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 2. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. 3. Department of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden. 4. Department of Surgery, Clinical Sciences, Lund University, Lund, Sweden. 5. Transplant Institute, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. 6. Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Abstract
BACKGROUND: Liver metastases are the most common cause of death for patients with colorectal cancer and affect up to half of the patients. Liver resection is an established method that can potentially be curative. For patients with extrahepatic disease (EHD), the role of liver surgery is less established. METHODS: This is a retrospective study based on data from the national quality registry SweLiv. Data were obtained between 2009 and 2015. SweLiv is a validated registry and has been in use since 2009, with coverage above 95%. Patients with liver metastases and EHD were analyzed and cross-checked against the national death cause registry for survival analysis. RESULTS: During the study period, 2,174 patients underwent surgery for colorectal liver metastases (CRLM), and 277 patients with EHD were treated with resection or ablation. The estimated median survival time for the entire cohort from liver resection/ablation was 40 months (95% CI, 32-47). The survival time for patients treated with liver resection was 45 months compared to 26 months for patients treated with ablation (95% CI 38-53, 18-33, P=0.001). A subgroup analysis of resected patients revealed that the group with pulmonary metastases had a significantly longer estimated median survival (50 months; 95% CI, 39-60) than the group with lymph node metastases (32 months; 95% CI, 7-58) or peritoneal carcinomatosis (28 months; 95% CI, 14-41) (P=0.022 and 0.012, respectively). Other negative prognostic factors were major liver resection and nonradical liver resection. CONCLUSIONS: For patients with liver metastases and limited EHD, liver resection results in prolonged survival compared to what can be expected from chemotherapy alone. 2020 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Liver metastases are the most common cause of death for patients with colorectal cancer and affect up to half of the patients. Liver resection is an established method that can potentially be curative. For patients with extrahepatic disease (EHD), the role of liver surgery is less established. METHODS: This is a retrospective study based on data from the national quality registry SweLiv. Data were obtained between 2009 and 2015. SweLiv is a validated registry and has been in use since 2009, with coverage above 95%. Patients with liver metastases and EHD were analyzed and cross-checked against the national death cause registry for survival analysis. RESULTS: During the study period, 2,174 patients underwent surgery for colorectal liver metastases (CRLM), and 277 patients with EHD were treated with resection or ablation. The estimated median survival time for the entire cohort from liver resection/ablation was 40 months (95% CI, 32-47). The survival time for patients treated with liver resection was 45 months compared to 26 months for patients treated with ablation (95% CI 38-53, 18-33, P=0.001). A subgroup analysis of resected patients revealed that the group with pulmonary metastases had a significantly longer estimated median survival (50 months; 95% CI, 39-60) than the group with lymph node metastases (32 months; 95% CI, 7-58) or peritoneal carcinomatosis (28 months; 95% CI, 14-41) (P=0.022 and 0.012, respectively). Other negative prognostic factors were major liver resection and nonradical liver resection. CONCLUSIONS: For patients with liver metastases and limited EHD, liver resection results in prolonged survival compared to what can be expected from chemotherapy alone. 2020 Annals of Translational Medicine. All rights reserved.
Authors: Universe Leung; Mithat Gönen; Peter J Allen; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: Yoshihiro Mise; Scott Kopetz; Reza J Mehran; Thomas A Aloia; Claudius Conrad; Kristoffer W Brudvik; Melissa W Taggart; Jean-Nicolas Vauthey Journal: Ann Surg Oncol Date: 2014-11-06 Impact factor: 5.344
Authors: Giovanni Brandi; Enrico Derenzini; Alfredo Falcone; Gianluca Masi; Fotios Loupakis; Andrea Pietrabissa; Antonio D Pinna; Giorgio Ercolani; Maria A Pantaleo; Stefania Di Girolamo; Gian L Grazi; Francesco de Rosa; Guido Biasco Journal: Clin Colorectal Cancer Date: 2013-06-14 Impact factor: 4.481
Authors: S K P John; S M Robinson; S Rehman; B Harrison; A Vallance; J J French; B C Jaques; R M Charnley; D M Manas; S A White Journal: Dig Surg Date: 2013-08-21 Impact factor: 2.588
Authors: Alice C Wei; Natalie G Coburn; Katharine S Devitt; Pablo E Serrano; Carol-Anne Moulton; Sean P Cleary; Calvin Law; Malcolm J Moore; Steven Gallinger Journal: Ann Surg Oncol Date: 2016-03-30 Impact factor: 5.344